|1.||Salazar, Andres M: 18 articles (01/2016 - 03/2005)|
|2.||Okada, Hideho: 5 articles (01/2015 - 01/2007)|
|3.||Kohanbash, Gary: 3 articles (01/2015 - 09/2010)|
|4.||Wong, J P: 3 articles (05/2009 - 03/2001)|
|5.||Bahjat, Frances R: 2 articles (01/2016 - 11/2012)|
|6.||Stenzel-Poore, Mary P: 2 articles (01/2016 - 11/2012)|
|7.||Packard, Amy E B: 2 articles (01/2016 - 11/2012)|
|8.||Stevens, Susan L: 2 articles (01/2016 - 11/2012)|
|9.||Gesuete, Raffaella: 2 articles (01/2016 - 11/2012)|
|10.||Butterfield, Lisa H: 2 articles (01/2015 - 01/2011)|
05/26/2009 - "Taken together, these results do support the potential role of TLR-3 and TLR-9 agonists such as Poly ICLC and LE Poly ICLC in protection against lethal seasonal and HPAI virus infection."
08/01/1987 - "The prophylactic efficacy of poly(ICLC) (stabilized, synthetic, double-stranded polyriboinosinic-polyribocytidylic acid) against Rift Valley fever virus infection in Swiss-Webster mice was dependent on the treatment schedule. "
08/01/1987 - "Ranking of prophylactic efficacy of poly(ICLC) against Rift Valley fever virus infection in mice by incremental relative risk of death."
04/01/2010 - "Similarly, in contrast to murine model, pathology of RSV infection was increased in cotton rats treated with poly ICLC. "
04/01/2010 - "Antiviral effect of poly ICLC against influenza virus and RSV was best achieved at high poly ICLC concentrations that, in the absence of virus infection, induced a strong IFN response. "
01/01/1988 - "Improved tumor response was obtained in mice receiving 1.5 mg/m2 or higher of Poly (ICLC). "
01/01/2007 - "These data suggest that poly-ICLC, which has been previously evaluated in clinical trials, can be effectively combined with tumor Ag-specific vaccine strategies, thereby providing a greater index of therapeutic efficacy."
08/01/2014 - "Therapeutic in situ autovaccination against solid cancers with intratumoral poly-ICLC: case report, hypothesis, and clinical trial."
01/01/2009 - "Treatment with poly-ICLC continued until tumor progression. "
01/01/2009 - "Treatment with poly-ICLC continued following the completion of RT to a maximum of 1 year or until tumor progression. "
|3.||Human Influenza (Influenza)
05/26/2009 - "Intranasal pre-treatment of mice with Poly ICLC and LE Poly ICLC provided high level of protection against lethal challenge with a highly lethal avian H5N1 influenza (HPAI) strain (A/H5N1/chicken/Henan clade 2), and against lethal seasonal influenza A/PR/8/34 [H1N1] and A/Aichi/2 [H3N2] virus strains. "
09/23/1977 - "The potentiation of the antibody response of young monkeys given a split-virus vaccine in combination with poly(ICLC) suggests that this vaccine-adjuvant combination may similarly provide a potentially useful alternative approach to the immunization of pediatric and young adult age groups against swine influenza."
04/01/2010 - "In this work, we analyzed the effect of poly ICLC on pulmonary responses to influenza and respiratory syncytial virus (RSV) infections in the cotton rat (Sigmodon hispidus) model. "
03/21/2001 - "Immunoprophylaxis using liposome-encapsulated double-stranded (ds) RNA poly (ICLC) provided complete and longer-lasting protection against influenza infection. "
03/21/2001 - "Antiviral antibody, interferon-gamma and poly (ICLC) were encapsulated in liposomes and they were evaluated for their ability to induce protective immunity against lethal influenza infection. "
01/15/2013 - "Glioma-bearing mice were vaccinated with Poly:ICLC plus OVA protein in the neck, hind leg, or foreleg for drainage into the cervical, inguinal, or axillary lymph nodes, respectively. "
09/01/2010 - "Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-alpha and IFN-gamma dependent manners."
01/01/2009 - "A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas."
09/01/2009 - "Based on these data, we have implemented a phase I/II vaccination study using type 1 polarizing DCs loaded with GAA peptides in combination with poly-ICLC in patients with recurrent malignant glioma."
01/01/2009 - "Based on this study, poly-ICLC does not improve 6moPFS in patients with recurrent anaplastic gliomas but may be worth further study in combination with agents such as temozolomide."
|5.||Glioblastoma (Glioblastoma Multiforme)
06/01/1996 - "Median Kaplan-Meier survival is 19 months for patients with glioblastomas who receive at least twice weekly poly-ICLC treatments. "
01/01/2009 - "A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05)."
01/01/2009 - "Our results suggest that poly-ICLC has activity against glioblastoma and may be worth further study in combination with agents such as temozolomide."
03/01/1982 - "(6 patients were glioblastoma, 1 was astrocytoma, and 2 were ependymoma.) In 2 patients, poly ICLC was administered once, in 2 patients twice, in 2 patients 3 times, and in 3 patients more than 5 times. "
10/01/2010 - "A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma."
|1.||Carboxymethylcellulose Sodium (Polycell)